Sign In

Login

Password

Forgot Password ? Sign Up

Melperone (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Melperone" in English language version.

refsWebsite
Global rank English rank
21nih.gov
4th place
4th place
17doi.org
2nd place
2nd place
11semanticscholar.org
11th place
8th place
3web.archive.org
1st place
1st place
1medicinescomplete.com
low place
low place
1ndrugs.com
low place
low place
1psychiatryonline.org
4,032nd place
6,573rd place
1unc.edu
1,538th place
1,042nd place
1patents.google.com
1,182nd place
725th place
1espacenet.com
800th place
676th place

doi.org

  • Borgström L, Larsson H, Molander L (1982). "Pharmacokinetics of parenteral and oral melperone in man". European Journal of Clinical Pharmacology. 23 (2): 173–6. doi:10.1007/BF00545974. PMID 7140807. S2CID 36697288.
  • Röhricht F, Gadhia S, Alam R, Willis M (2012). "Auditing clinical outcomes after introducing off-licence prescribing of atypical antipsychotic melperone for patients with treatment refractory schizophrenia". TheScientificWorldJournal. 2012: 512047. doi:10.1100/2012/512047. PMC 3330679. PMID 22566771.
  • Whiskey E, Vavrova M, Gaughran F, Taylor D (February 2011). "Melperone in treatment-refractory schizophrenia: a case series". Therapeutic Advances in Psychopharmacology. 1 (1): 19–23. doi:10.1177/2045125311399800. PMC 3736899. PMID 23983923.
  • Meltzer HY, Sumiyoshi T, Jayathilake K (December 2001). "Melperone in the treatment of neuroleptic-resistant schizophrenia". Psychiatry Research. 105 (3): 201–9. doi:10.1016/s0165-1781(01)00346-8. PMID 11814539. S2CID 23311317.
  • Sumiyoshi T, Meltzer HY, Jayathilake K (2004). "Melperone, an atypical antipsychotic drug, in the treatment of schizophrenia: dose-response analysis on effectiveness and tolerability, and efficacy for treatment-resistant schizophrenia and cognitive function". International Clinical Psychopharmacology. 19 (3): 184. doi:10.1097/00004850-200405000-00039.
  • Friedman JH (May 2012). "Melperone is ineffective in treating Parkinson's disease psychosis". Movement Disorders. 27 (6): 803–4. doi:10.1002/mds.24942. PMID 22362330. S2CID 41211677.
  • Pöldinger WJ (1984). "Melperone in low doses in anxious neurotic patients. A double-blind placebo-controlled clinical study". Neuropsychobiology. 11 (3): 181–6. doi:10.1159/000118074. PMID 6147789.
  • Bobo WV, Jayathilake K, Lee MA, Meltzer HY (April 2010). "Changes in weight and body mass index during treatment with melperone, clozapine and typical neuroleptics". Psychiatry Research. 176 (2–3): 114–9. doi:10.1016/j.psychres.2009.03.026. PMID 20199813. S2CID 25366120.
  • Bobo WV, Jayathilake K, Lee MA, Meltzer HY (July 2009). "Melperone, an aytpical antipsychotic drug with clozapine-like effect on plasma prolactin: contrast with typical neuroleptics". Human Psychopharmacology. 24 (5): 415–22. doi:10.1002/hup.1036. PMID 19551763. S2CID 25812368.
  • Molander L, Borgström L (1983). "Sedative effects and prolactin response to single oral doses of melperone". Psychopharmacology. 79 (2–3): 142–7. doi:10.1007/bf00427801. PMID 6133301. S2CID 392818.
  • Hui WK, Mitchell LB, Kavanagh KM, Gillis AM, Wyse DG, Manyari DE, Duff HJ (January 1990). "Melperone: electrophysiologic and antiarrhythmic activity in humans". Journal of Cardiovascular Pharmacology. 15 (1): 144–9. doi:10.1097/00005344-199001000-00023. PMID 1688972. S2CID 40589560.
  • Bjerkenstedt L (1989). "Melperone in the treatment of schizophrenia". Acta Psychiatrica Scandinavica. Supplementum. 352: 35–9. doi:10.1111/j.1600-0447.1989.tb06434.x. PMID 2479227. S2CID 7828966.
  • Molander L, Birkhed D (1981). "Effect of single oral doses of various neuroleptic drugs on salivary secretion rate, pH, and buffer capacity in healthy subjects". Psychopharmacology. 75 (2): 114–8. doi:10.1007/bf00432171. PMID 6119724. S2CID 780924.
  • Gahr M, Gastl R, Kölle MA, Schönfeldt-Lecuona C, Freudenmann RW (February 2012). "Successful treatment of schizophrenia with melperone augmentation in a patient with phenotypic CYP2D6 ultrarapid metabolization: a case report". Journal of Medical Case Reports. 6 (1): 49. doi:10.1186/1752-1947-6-49. PMC 3298719. PMID 22309430.
  • Köhnke MD, Lutz U, Wiatr G, Schwärzler F, Weller B, Schott K, Buchkremer G (April 2006). "Cytochrome P450 2D6 dependent metabolization of risperidone is inhibited by melperone". European Journal of Clinical Pharmacology. 62 (4): 333–4. doi:10.1007/s00228-006-0098-y. PMID 16534635. S2CID 13168439.
  • Grözinger M, Dragicevic A, Hiemke C, Shams M, Müller MJ, Härtter S (January 2003). "Melperone is an inhibitor of the CYP2D6 catalyzed O-demethylation of venlafaxine". Pharmacopsychiatry. 36 (1): 3–6. doi:10.1055/s-2003-38084. PMID 12649767. S2CID 260242201.
  • Seeman P (January 2004). "Atypical Antipsychotics: Mechanism of Action" (PDF). FOCUS: The Journal of Lifelong Learning in Psychiatry. 2 (1): 48–58. doi:10.1176/foc.2.1.48. PMID 11873706. Archived from the original (PDF) on 2013-11-27.

espacenet.com

worldwide.espacenet.com

  • BE651144 idem Erik Harry Hernestam Sven, et al.GB 1029220  (1966 to Ferrosan); CA, 63, 13244c

medicinescomplete.com

ndrugs.com

nih.gov

pubmed.ncbi.nlm.nih.gov

  • Borgström L, Larsson H, Molander L (1982). "Pharmacokinetics of parenteral and oral melperone in man". European Journal of Clinical Pharmacology. 23 (2): 173–6. doi:10.1007/BF00545974. PMID 7140807. S2CID 36697288.
  • Röhricht F, Gadhia S, Alam R, Willis M (2012). "Auditing clinical outcomes after introducing off-licence prescribing of atypical antipsychotic melperone for patients with treatment refractory schizophrenia". TheScientificWorldJournal. 2012: 512047. doi:10.1100/2012/512047. PMC 3330679. PMID 22566771.
  • Whiskey E, Vavrova M, Gaughran F, Taylor D (February 2011). "Melperone in treatment-refractory schizophrenia: a case series". Therapeutic Advances in Psychopharmacology. 1 (1): 19–23. doi:10.1177/2045125311399800. PMC 3736899. PMID 23983923.
  • Meltzer HY, Sumiyoshi T, Jayathilake K (December 2001). "Melperone in the treatment of neuroleptic-resistant schizophrenia". Psychiatry Research. 105 (3): 201–9. doi:10.1016/s0165-1781(01)00346-8. PMID 11814539. S2CID 23311317.
  • Friedman JH (May 2012). "Melperone is ineffective in treating Parkinson's disease psychosis". Movement Disorders. 27 (6): 803–4. doi:10.1002/mds.24942. PMID 22362330. S2CID 41211677.
  • Pöldinger WJ (1984). "Melperone in low doses in anxious neurotic patients. A double-blind placebo-controlled clinical study". Neuropsychobiology. 11 (3): 181–6. doi:10.1159/000118074. PMID 6147789.
  • Bobo WV, Jayathilake K, Lee MA, Meltzer HY (April 2010). "Changes in weight and body mass index during treatment with melperone, clozapine and typical neuroleptics". Psychiatry Research. 176 (2–3): 114–9. doi:10.1016/j.psychres.2009.03.026. PMID 20199813. S2CID 25366120.
  • Bobo WV, Jayathilake K, Lee MA, Meltzer HY (July 2009). "Melperone, an aytpical antipsychotic drug with clozapine-like effect on plasma prolactin: contrast with typical neuroleptics". Human Psychopharmacology. 24 (5): 415–22. doi:10.1002/hup.1036. PMID 19551763. S2CID 25812368.
  • Molander L, Borgström L (1983). "Sedative effects and prolactin response to single oral doses of melperone". Psychopharmacology. 79 (2–3): 142–7. doi:10.1007/bf00427801. PMID 6133301. S2CID 392818.
  • Hui WK, Mitchell LB, Kavanagh KM, Gillis AM, Wyse DG, Manyari DE, Duff HJ (January 1990). "Melperone: electrophysiologic and antiarrhythmic activity in humans". Journal of Cardiovascular Pharmacology. 15 (1): 144–9. doi:10.1097/00005344-199001000-00023. PMID 1688972. S2CID 40589560.
  • Bjerkenstedt L (1989). "Melperone in the treatment of schizophrenia". Acta Psychiatrica Scandinavica. Supplementum. 352: 35–9. doi:10.1111/j.1600-0447.1989.tb06434.x. PMID 2479227. S2CID 7828966.
  • Molander L, Birkhed D (1981). "Effect of single oral doses of various neuroleptic drugs on salivary secretion rate, pH, and buffer capacity in healthy subjects". Psychopharmacology. 75 (2): 114–8. doi:10.1007/bf00432171. PMID 6119724. S2CID 780924.
  • Kirkegaard A, Kirkegaard G, Geismar L, Christensen I (1981). "Additional studies on side effects of melperone in long-term therapy for 1 to 15 years in psychiatric patients". Arzneimittel-Forschung. 31 (4): 737–40. PMID 6113835.
  • Christensen I, Geismar L, Kirkegaard A, Kirkegaard G (May 1986). "Additional studies on side effects of melperone in long-term therapy for 1-20 years in psychiatric patients". Arzneimittel-Forschung. 36 (5): 855–60. PMID 2873821.
  • Gahr M, Gastl R, Kölle MA, Schönfeldt-Lecuona C, Freudenmann RW (February 2012). "Successful treatment of schizophrenia with melperone augmentation in a patient with phenotypic CYP2D6 ultrarapid metabolization: a case report". Journal of Medical Case Reports. 6 (1): 49. doi:10.1186/1752-1947-6-49. PMC 3298719. PMID 22309430.
  • Köhnke MD, Lutz U, Wiatr G, Schwärzler F, Weller B, Schott K, Buchkremer G (April 2006). "Cytochrome P450 2D6 dependent metabolization of risperidone is inhibited by melperone". European Journal of Clinical Pharmacology. 62 (4): 333–4. doi:10.1007/s00228-006-0098-y. PMID 16534635. S2CID 13168439.
  • Grözinger M, Dragicevic A, Hiemke C, Shams M, Müller MJ, Härtter S (January 2003). "Melperone is an inhibitor of the CYP2D6 catalyzed O-demethylation of venlafaxine". Pharmacopsychiatry. 36 (1): 3–6. doi:10.1055/s-2003-38084. PMID 12649767. S2CID 260242201.
  • Seeman P (January 2004). "Atypical Antipsychotics: Mechanism of Action" (PDF). FOCUS: The Journal of Lifelong Learning in Psychiatry. 2 (1): 48–58. doi:10.1176/foc.2.1.48. PMID 11873706. Archived from the original (PDF) on 2013-11-27.

ncbi.nlm.nih.gov

patents.google.com

psychiatryonline.org

semanticscholar.org

api.semanticscholar.org

  • Borgström L, Larsson H, Molander L (1982). "Pharmacokinetics of parenteral and oral melperone in man". European Journal of Clinical Pharmacology. 23 (2): 173–6. doi:10.1007/BF00545974. PMID 7140807. S2CID 36697288.
  • Meltzer HY, Sumiyoshi T, Jayathilake K (December 2001). "Melperone in the treatment of neuroleptic-resistant schizophrenia". Psychiatry Research. 105 (3): 201–9. doi:10.1016/s0165-1781(01)00346-8. PMID 11814539. S2CID 23311317.
  • Friedman JH (May 2012). "Melperone is ineffective in treating Parkinson's disease psychosis". Movement Disorders. 27 (6): 803–4. doi:10.1002/mds.24942. PMID 22362330. S2CID 41211677.
  • Bobo WV, Jayathilake K, Lee MA, Meltzer HY (April 2010). "Changes in weight and body mass index during treatment with melperone, clozapine and typical neuroleptics". Psychiatry Research. 176 (2–3): 114–9. doi:10.1016/j.psychres.2009.03.026. PMID 20199813. S2CID 25366120.
  • Bobo WV, Jayathilake K, Lee MA, Meltzer HY (July 2009). "Melperone, an aytpical antipsychotic drug with clozapine-like effect on plasma prolactin: contrast with typical neuroleptics". Human Psychopharmacology. 24 (5): 415–22. doi:10.1002/hup.1036. PMID 19551763. S2CID 25812368.
  • Molander L, Borgström L (1983). "Sedative effects and prolactin response to single oral doses of melperone". Psychopharmacology. 79 (2–3): 142–7. doi:10.1007/bf00427801. PMID 6133301. S2CID 392818.
  • Hui WK, Mitchell LB, Kavanagh KM, Gillis AM, Wyse DG, Manyari DE, Duff HJ (January 1990). "Melperone: electrophysiologic and antiarrhythmic activity in humans". Journal of Cardiovascular Pharmacology. 15 (1): 144–9. doi:10.1097/00005344-199001000-00023. PMID 1688972. S2CID 40589560.
  • Bjerkenstedt L (1989). "Melperone in the treatment of schizophrenia". Acta Psychiatrica Scandinavica. Supplementum. 352: 35–9. doi:10.1111/j.1600-0447.1989.tb06434.x. PMID 2479227. S2CID 7828966.
  • Molander L, Birkhed D (1981). "Effect of single oral doses of various neuroleptic drugs on salivary secretion rate, pH, and buffer capacity in healthy subjects". Psychopharmacology. 75 (2): 114–8. doi:10.1007/bf00432171. PMID 6119724. S2CID 780924.
  • Köhnke MD, Lutz U, Wiatr G, Schwärzler F, Weller B, Schott K, Buchkremer G (April 2006). "Cytochrome P450 2D6 dependent metabolization of risperidone is inhibited by melperone". European Journal of Clinical Pharmacology. 62 (4): 333–4. doi:10.1007/s00228-006-0098-y. PMID 16534635. S2CID 13168439.
  • Grözinger M, Dragicevic A, Hiemke C, Shams M, Müller MJ, Härtter S (January 2003). "Melperone is an inhibitor of the CYP2D6 catalyzed O-demethylation of venlafaxine". Pharmacopsychiatry. 36 (1): 3–6. doi:10.1055/s-2003-38084. PMID 12649767. S2CID 260242201.

unc.edu

pdsp.med.unc.edu

  • Roth BL, Driscol J. "PDSP Ki Database". Psychoactive Drug Screening Program (PDSP). University of North Carolina at Chapel Hill and the United States National Institute of Mental Health. Archived from the original on 2013-11-08. Retrieved 2013-10-14.

web.archive.org